Ascendia

  MARKET NEWS

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
Absci Announces Collaboration With AstraZeneca to Advance AI-Driven Oncology Candidate
Samsung Bioepis Secures US License Date for SB17, a Proposed Biosimilar to Stelara
Orchard Therapeutics Receives US FDA Fast Track Designation for OTL-203 in MPS-IH
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
BiomX Announces Positive Topline Results From Part 2 of the Phase 1b/2a Trial Evaluating Treatment for Chronic Pulmonary Infections in Patients With Cystic Fibrosis

  FEATURED EDITORIAL

  COMPANY PROFILE


HTD Biosystems is your expert in drug development, with a strong track record of success in bringing innovative therapies from discovery to the clinic. Our team includes seasoned professionals with a wealth of experience in drug discovery, preclinical development, clinical development, and manufacturing. HTD Biosystems specializes in customized lyophilization and biotech drug development services, utilizing advanced techniques and extensive experience to deliver high-quality pharmaceutical products. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Oxford Biomedica Signs Agreement to Acquire ABL Europe, Consolidating Position as a Global Pure-Play CDMO

Oxford Biomedica Signs Agreement to Acquire ABL Europe, Consolidating Position as a Global Pure-Play CDMO

Oxford Biomedica plc recently announced it has entered into a sale and purchase agreement with TSGH SAS, a subsidiary of Institut Mérieux SA, for the acquisition of….

AbbVie to Acquire ImmunoGen, Including its Flagship Cancer Therapy, Expanding Solid Tumor Portfolio

AbbVie to Acquire ImmunoGen, Including its Flagship Cancer Therapy, Expanding Solid Tumor Portfolio

AbbVie Inc. and ImmunoGen, Inc. recently announced a definitive agreement under which AbbVie will acquire ImmunoGen and its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class….

Ardena's New Aseptic Fill-Finish Plant in Ghent Receives GMP License

Ardena's New Aseptic Fill-Finish Plant in Ghent Receives GMP License

Ardena, a leading Contract Development and Manufacturing Organization (CDMO) specializing in bringing molecules to clinic, has been granted a Good Manufacturing Practice (GMP) license by the….

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung

Oxford BioTherapeutics recently announced the US FDA has granted Fast Track designation to BI 764532 for the potential treatment of advanced or metastatic large-cell neuroendocrine carcinoma of….

  WHITEPAPERS & WEBINARS

WEBINAR - 2024 Trends in Topical Drug Delivery: Insights & Innovation

WEBINAR - 2024 Trends in Topical Drug Delivery: Insights & Innovation

This webinar will discuss some of the key trends from these leaders in the topical market on both a global and regional level, including the increased importance of sensory properties and the rise in non-conventional product formats, among others…..

WEBINAR - Enabling Upstream Intensified Bioprocessing

WEBINAR - Enabling Upstream Intensified Bioprocessing

Intensified upstream bioprocesses are being developed to increase productivity while reducing footprint, costs, and timelines for manufacturing. The higher cell densities generated by….

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

Join us for an upcoming webinar that delves into a crucial issue in the pharmaceutical industry. Recent research has revealed a surprising fact: the pharmaceutical sector has a larger carbon footprint than even the automotive industry, especially when we consider the entire supply chain’s impact on

  WHITEPAPERS & WEBINARS

WHITEPAPER - Minimizing API Supply Chain Risks

WHITEPAPER - Minimizing API Supply Chain Risks

By the time your API is brought to a contract manufacturing organization (CMO), you have already put extensive amounts of resources into developing it. It becomes essential that you optimize your API supply chain to be aware of potential risks

…

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

Honeywell Aclar® thermoformable film enables pharmaceutical and medical device companies to achieve their sustainability commitments.

Aclar® film not only delivers a high moisture barrier to protect medicines, but it also reduces pack size, reduces waste, and reduces carbon emissions, compared

…

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

By: Dr. Bahar Yeniad and Dr. Pieter van Delft

Experts in copolymer microstructures have an important role to play in selecting biomaterials that can deliver desired performance of (bio)medical products. But how does microstructure link to the rate of API …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

December 13 – Inhalation Delivery
December 20 – ODT/Fast Dissolve